Ann: Phylomer licenced to Le metier de Beaute , page-33

Here's a section from the Neuroprotective peptide inhibitors of AP-1 US Patent 8063012

http://www.freepatentsonline.com/8063012.html

The present inventors have shown herein that five AP-1 signaling inhibitory peptides, designated PYC19, PYC35, PYC36, PYC38/39 and PYC41, are also neuroprotective in in vitro and in vivo models of neurological damage in humans. The sequences of these peptides are set forth in Table 1 herein and the accompanying Sequence Listing. In particular, the Phylomer™ peptides are neuroprotective following glutamate and/or NMDA excitotoxicity in primary cortical neuronal cultures, establishing their relevance to therapy of disorders such as migraine, stroke, traumatic brain injury, epilepsy and neurodegenerative disorders including Parkinson's Disease (PD), Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS). The inventors have also demonstrated that AP-1 signaling inhibitory Phylomer™ peptides, in particular PYC35 and/or PYC36, protect cultured cortical neurons in an in vitro model of cerebral ischemia i.e., Oxygen Glucose Deprivation (OGD). The data presented herein also demonstrate that AP-1 signaling inhibitory Phylomer™ peptides, in particular PYC35 and/or PYC36, are neuroprotective in vivo, in a head injury model of global cerebral ischemia, as determined by MAP2 immunoreactivity (a marker of neuron loss in brain tissue) following administration of peptides. In particular, peptide PYC35 provides significant neuroprotection following acute cortical injury of rat brain tissue in situ, including: (i) reduced loss of neurons as determined by MAP2 immunoreactivity; (ii) reduced astrogliosis as determined by glial fibrillary acidic protein immunoreactivity; and (iii) reduced microglial activation as determined by ferritin immunoreactivity. These data are consistent with a neuroprotective function and therapeutic potential in the treatments of head injury and/or ischemia.